Items where authors include "Garg, M."

Article

Kulasekararaj, A. orcid.org/0000-0003-3180-3570, Cavenagh, J., Dokal, I. et al. (14 more authors) (2024) Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. British Journal of Haematology. ISSN 0007-1048

Glasbey, J.C., Abbott, T.E.F., Ademuyiwa, A. et al. (4500 more authors) (2022) Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries. The Lancet, 400 (10363). pp. 1607-1617. ISSN 0140-6736

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Striha, A., Ashcroft, A.J., Hockaday, A. et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. ISSN 1745-6215

Harris, A.T., Garg, M., Yang, X.B. et al. (5 more authors) (2009) Raman spectroscopy and advanced mathematical modelling in the discrimination of human thyroid cell lines. Head & Neck Oncology , 1. ISSN 1472-6963

Proceedings Paper

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .